

Erratum

Erratum to “Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs” [Antiv. Res. 73 (2007) 169–174]

A. Scagliarini^{a,*}, C.J. McInnes^b, L. Gallina^a, F. Dal Pozzo^a, L. Scagliarini^a,
R. Snoeck^c, S. Prosperi^a, J. Sales^d, J.A. Gilray^b, P.F. Nettleton^b

^a *Dipartimento di Sanità Pubblica Veterinaria e Patologia Animale, Alma Mater Studiorum, Bologna, Italy*

^b *Moredun Research Institute, Pentlands Science Park, Edinburgh EH26 0PZ, UK*

^c *Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium*

^d *Biomathematics & Statistics Scotland, The King's Buildings, James Clerk Maxwell Building, Edinburgh EH9 3JZ, UK*

Abstract

(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (HPMPC, cidofovir, CDV, Vistide[®]) is an acyclic nucleoside analogue with a potent and selective activity against a broad spectrum of DNA viruses including the poxviruses. In this study we present the results of different treatment regimens in lambs experimentally infected with orf virus with different cidofovir formulations prepared in Beeler basis and Unguentum M. Our results show that choice of excipient, concentration of cidofovir and treatment regimen were all important to the clinical outcome of the therapy. Whilst one particular regimen appeared to exacerbate the lesion, treatment with 1% (w/v) cidofovir cream, prepared in Beeler basis, for 4 consecutive days did result in milder lesions that resolved more quickly than untreated lesions. Furthermore the scabs of the treated animals contained significantly lower amounts of viable virus meaning there should be less contamination of the environment with virus than would normally occur.

© 2008 Elsevier B.V. All rights reserved.

Keywords: Orf virus; Contagious ecthyma; Cidofovir; HPMPC; Topical treatment; Formulation

The publisher regrets that an error occurred in the abstract of the printed version of the above article. The corrected abstract is now reproduced above.

DOI of original article: [10.1016/j.antiviral.2006.09.008](https://doi.org/10.1016/j.antiviral.2006.09.008).

* Corresponding author at: Dipartimento di Sanità Pubblica Veterinaria e Patologia Animale, Sezione Malattie Infettive, Facoltà di Medicina Veterinaria, Università degli Studi di Bologna, Via Tolara di Sopra, 50, 40064 Ozzano Emilia, Bologna, Italy. Tel.: +39 051 2097002; fax: +39 051 2097039.

E-mail addresses: ascagliarini@vet.unibo.it (A. Scagliarini), Colin.McInnes@moredun.ac.uk (C.J. McInnes), lgallina@vet.unibo.it (L. Gallina), fdalpozzo@vet.unibo.it (F. Dal Pozzo), Robert.Snoeck@rega.kuleuven.ac.be (R. Snoeck), jill@bioss.sari.ac.uk (J. Sales), nettp@mri.sari.ac.uk (P.F. Nettleton).